ARCH's lat­est biotech, tar­get­ing can­cer re­cur­rence, emerges from Co­lum­bia pro­fes­sor who worked on Biden's moon­shot

TFC Ther­a­peu­tics, a new ARCH Ven­ture Part­ners biotech, on Thurs­day un­veiled a mis­sion to thwart the re­turn of can­cer and its spread to oth­er parts of the body with new bi­o­log­ics.

The ear­ly-stage New York start­up builds off four decades of can­cer re­search out of Co­lum­bia Uni­ver­si­ty med­ical pro­fes­sor Azra Raza.

TFC has the ex­clu­sive li­cense to de­vel­op a drug dis­cov­ery plat­form tar­get­ing tu­mor macrophage hy­brid, or TMH, cells based on work out of Raza’s lab along­side prin­ci­pal sci­en­tist and as­sis­tant pro­fes­sor Ab­dul­lah Ali. Raza di­rects the MDS Cen­ter at Co­lum­bia and has led re­search on myelodys­plas­tic syn­drome, var­i­ous leukemias and oth­er can­cers across a ca­reer span­ning Rush Uni­ver­si­ty, the Uni­ver­si­ty of Mass­a­chu­setts and else­where be­fore mov­ing to her cur­rent base in 2010.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER